E. Douglas Kramer

SVP, Clinical Pharmacovigilance & Regulatory Affairs at Athenex

Doug has over 20 years of experience in drug development, regulatory affairs and pharmaceutical risk management. He has been involved in successful approvals of treatments for addiction (including nicotine replacement and buprenorphine for opioid dependence), opioid analgesics, and IV Temodar for glioblastoma. His work has included international drug regulatory issues and strategy and development of risk management plans for post marketing drug safety. Doug holds a Doctor of Medicine (MD) degree from Columbia University and a Bachelor of Arts degree in Chemistry from Vassar College.

Timeline

  • SVP, Clinical Pharmacovigilance & Regulatory Affairs

    Current role

View in org chart